Regeneron’s Dupixent for Rhinosinusitis with Nasal Polyp

FDA has expanded the approval of Regeneron’s Dupixent (dupilumab) for use with other medicines to treat chronic rhinosinusitis with nasal polyposis (CRSwNP) in adults whose disease is not controlled. CRSwNP can be a debilitating condition, with many patients opting for systemic steroids or nasal surgery. The condition alos often occurs in combination with severe asthma.

“Dupixent is the first FDA approved medicine for adults with chronic rhinosinusitis with nasal polyposis, and the only approved therapy shown to shrink nasal polyp size and also improve the signs and symptoms of the associated chronic rhinosinusitis,” the company says. Dupixent is a fully-human monoclonal antibody that inhibits the signalling of interleukin-4 (IL-4) and interleukin-13 (IL-13), two proteins that play a central role in Type 2 inflammation, it adds.

The therapy is also approved adults and adolescents with atopic dermatitis or moderate-to-severe asthma.